TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

STENDRA

AVANAFIL Phosphodiesterase 5 Inhibitors
Approved 2012-04-27
4
Indications
--
Phase 3 Trials
13
Years on Market

Details

Status
Prescription
First Approved
2012-04-27
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: AVANAFIL

STENDRA Approval History

Loading approval history...

What STENDRA Treats

1 indications

STENDRA is approved for 1 conditions since its original approval in 2012. These indications span multiple therapeutic areas including oncology, immunology, and more.

  • Erectile Dysfunction
Source: FDA Label
πŸ”¬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...
⭐

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
πŸ“Š

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

STENDRA FDA Label Details

Pro

Indications & Usage

FDA Label (PDF)

Avanafil tablets are a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction in adult males. Avanafil tablet is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.